AstraZeneca’s iCaReMe Global Registry: A Game Changer in Real-World Data Collection

AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.

AstraZeneca is currently conducting the iCaReMe Global Registry study, officially titled ‘Real-world Multinational Registry to Determine Management and Quality of Care of Patients With Type 2 Diabetes, Hypertension, Heart Failure and/or Chronic Kidney Diseases.’ The study aims to gather real-world data on patient characteristics, disease management, healthcare utilization, and outcomes for these conditions, highlighting its significance in improving patient care globally.

The study does not involve any specific intervention or treatment. Instead, it focuses on collecting observational data to understand the management and quality of care for patients with the specified conditions.

This is an observational study utilizing a cloud-based electronic case report form (eCRF) for both prospective and retrospective data collection. It is open to all physicians managing patients with type 2 diabetes, hypertension, heart failure, or chronic kidney disease worldwide, and it aims to provide comprehensive insights into real-world clinical practices.

The study commenced on February 17, 2018, with its primary completion date yet to be determined. The most recent update was submitted on August 11, 2025, indicating ongoing data collection and analysis.

The iCaReMe Global Registry could potentially impact AstraZeneca’s stock performance positively by positioning the company as a leader in real-world evidence generation, which is increasingly valued in the healthcare industry. This could enhance investor sentiment, especially as the demand for real-world data grows among competitors and stakeholders.

The study is ongoing, with further details available on the ClinicalTrials portal.